Cox D A, Matlib M A
Lilly Research Laboratories, Indianapolis, IN 46285.
Trends Pharmacol Sci. 1993 Nov;14(11):408-13. doi: 10.1016/0165-6147(93)90063-P.
Evidence has accumulated in the past decade suggesting that Ca2+ acts as a second messenger not only in the cytosol of the heart to regulate contractility, but also within the mitochondria to regulate the rate of oxidative ATP synthesis. Just as elucidation of the second messenger pathways for Ca2+ in the cytosol has led to the development of pharmacological interventions that alter mechanical functioning of the heart, understanding the role of Ca2+ as a second messenger within the mitochondria and the mechanisms by which this organelle transports and regulates Ca2+ has exciting potential for developing pharmacological interventions that alter myocardial energy metabolism. In this article, David Cox and Mohammed Matlib discuss the potential consequences of pharmacologically increasing the intramitochondrial Ca2+ concentration on myocardial energy metabolism, and suggest some pathological conditions in which such an effect may be beneficial.
在过去十年中,越来越多的证据表明,Ca2+不仅作为第二信使在心脏细胞质中调节收缩力,还在线粒体内调节氧化ATP合成的速率。正如对细胞质中Ca2+第二信使途径的阐明导致了改变心脏机械功能的药理学干预措施的发展一样,了解Ca2+作为线粒体内第二信使的作用以及该细胞器运输和调节Ca2+的机制,对于开发改变心肌能量代谢的药理学干预措施具有令人兴奋的潜力。在本文中,大卫·考克斯和穆罕默德·马特利布讨论了通过药理学方法增加线粒体内Ca2+浓度对心肌能量代谢的潜在影响,并提出了一些这种效应可能有益的病理状况。